Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quantum Computing Inc (QUBT) vs BIO-TECHNE Corp (TECH) Price & Performance

Quantum Computing IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Quantum Computing Inc vs BIO-TECHNE Corp — how do they compare? Quantum Computing Inc trades at $7.92 (market cap $1.85B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 6× Quantum Computing Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.

QUBTTECH
Market Cap
$1.85B$11.16B
Sector
TechnologyHealth
52-Week High
$24.62$72.12
52-Week Low
$6.31$43.31
Enterprise Value
$871.49M$11.24B
Dividend Yield
0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quantum Computing Inc

Quantum Computing Inc. (QUBT) trades at $7.92, up 1.54% on the day, while technical indicators signal a bearish trend. The company reported minimal revenue of $682K in 2025 with a net loss of $18.67M, reflecting negative profit margins. Recent news highlights a shareholder investigation into potential fiduciary breaches, though some analysts remain optimistic about commercial growth prospects in quantum computing.

Despite a high analyst consensus price target of $26.00 and 75% buy ratings, QUBT faces significant financial risks including cash burn, negative earnings, and competitive pressures. The stock's outlook hinges on successful commercialization and revenue scaling, but current fundamentals suggest high volatility and speculative investment appeal.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.

The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quantum Computing Inc

Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.

Read more on QUBT

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH